Update recent PSMA: Docs did it to me... - Advanced Prostate...

Advanced Prostate Cancer

21,056 members26,262 posts

Update recent PSMA

kainasar profile image
19 Replies

Docs did it to me again with the usual bad news.

Uptake in new lymph node locations in pelvis. the radiotherapy failed, and preclude more treatment on new nodal areas. (according to Docs.)

So expect to add to ADT, abi or enza or darolutamide in a short while, with PSA going up on a fast double.

Trying to find out if Nubeqa is worth it regarding technical difference in progression and overall survival, compared to abiraterone. Abi may be better in some ways.

thanks.

Written by
kainasar profile image
kainasar
To view profiles and participate in discussions please or .
Read more about...
19 Replies
Tall_Allen profile image
Tall_Allen

Could you please fill out more info in your profile? What exactly was previously treated with RT? Where were the lymph nodes on PSMA and how many? Any bone metastases?

Nubeqa is not approved for recurrence, although your MO may be able to get it approved.

kainasar profile image
kainasar in reply to Tall_Allen

Thanks TA. In 6/2012 had IMRT then BR 10/12. May 2018 had salvage min invasive robotic prostate removal, in August BR was obvious. Began Degarelix 3/19. After PSMA 7/23, and PSA doubling, I was given SBRT to 3 lymph nodes on my right leg-hip juncture, 12/23. On continuing ADT, PSA went down to .96 in 1/24 then doubled up to 2.14 (3/12/24) . New PSMA ordered showed 3 LN on my left side - 2 at iliac then then another on left at hip- leg juncture. All 3 have prominent uptake. One of the 3 zapped with SBRT (on my right) also showed uptake, and a fourth seems to be emerging at that region. Rad Onc said no to further SBRT, since then. No bone mets indicated. No visceral. Pursuing second opinion on scan. Meeting with MO at DFCI for next steps.

Tall_Allen profile image
Tall_Allen in reply to kainasar

Chasing after single pelvic lymph node metastases was certainly a bad idea, but because it has spread to your inguinal LN, it is out of the area where radiation can be curative. Intensive hormone therapy is your best option. 2 recent trials (EMBARK and PRESTO) have proven the benefit of a limited run of Erleada or Xtandi.

prostatecancer.news/2022/09...

prostatecancer.news/2023/05...

kainasar profile image
kainasar in reply to Tall_Allen

Thank you. Will study those. Ive read Enzalutamide has an advantage over Nubeqa.

Tall_Allen profile image
Tall_Allen in reply to kainasar

There has never been a randomized comparison.

kainasar profile image
kainasar in reply to Tall_Allen

Found study that seems to confirm effectiveness of Darolut vs mHSPC, but have found none yet that nail down Daro vs mCPRC, or CPRC.

Tall_Allen profile image
Tall_Allen in reply to kainasar

Please show what you found. To my knowledge the only published trial using darolutamide in mHSPC was a triplet trial (ARASENS) where it is only combined with docetaxel. The only other trial (ARAMIS) where its use has been approved was for non-metastatic CRPC.

kainasar profile image
kainasar in reply to Tall_Allen

This is one from 2020 of Daro on nmCRPC vs placebo (with ADT) Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer - PubMed

Tall_Allen profile image
Tall_Allen in reply to kainasar

nm=non-metastatic

kainasar profile image
kainasar in reply to Tall_Allen

yes

kainasar profile image
kainasar in reply to Tall_Allen

Looked at ARASENS. This one is interesting, that could show useful combination for mcprc also. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis - PubMed

Tall_Allen profile image
Tall_Allen in reply to kainasar

ONLY with docetaxel.

kainasar profile image
kainasar in reply to Tall_Allen

Yes. This is interesting regarding Daro - Doca pubmed.ncbi.nlm.nih.gov/380...

kainasar profile image
kainasar in reply to kainasar

This study is part of Arasens, with evidence of Darolutamide effectiveness against CPRC metastasis.

pubmed.ncbi.nlm.nih.gov/360...

Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial - PubMed

PaxNova profile image
PaxNova

Kainasar, your doctors failed to inform you that SBRT and Proton Beam can both be used on patients that had prior radiation. Are you in the States or elsewhere?

kainasar profile image
kainasar in reply to PaxNova

Yes I am seeing docs at DanaFarber/Brigham Womens in Boston

kainasar profile image
kainasar in reply to PaxNova

Expert said radiotherapy would not completely shutdown all the cancer.

God_Loves_Me profile image
God_Loves_Me

one advice listen to Tall Allen

kainasar profile image
kainasar

Darolutamide linked to longer time to treatment discontinuation.

urologytimes.com/view/darol...

You may also like...

Update on LU177 PSMA results.

After 3 injections (4th tomorrow) my PSA has dropped from 110 to 0.56 today so great results in my...

Update after LU 177 PSMA

activity and PSA at 4.9. I was actually pleased with the 4.9 since before LU177 my PSA was...

Excellent response to Ac-225-PSMA-617 in South Africa (update)

African trial info based on new info on 73 treated patients. In 79% of patients, PSA declined by...

Update on Lu psma treatment-psa increasing

reasons.The psa was 6.2 on 17th oct and ALP 120.Today he got tested again and now yhe psa has risen...

Update post follow up PSMA PET/CT

somehow got my insurance to pay for even though my PSA was undetectable. It defined a abdominal...